Anavex Life Sciences (AVXL) Prepaid Assets (2011 - 2025)
Anavex Life Sciences (AVXL) reported Prepaid Assets of $396000.0 for Q4 2025, down 44.3% on a YoY basis from $711000.0 in Q4 2024, and down 7.69% sequentially from $429000.0 in Q3 2025.
Anavex Life Sciences (AVXL) Prepaid Assets (2011 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 14 years of Prepaid Assets data on file, last reported at $396000.0 in Q4 2025.
- For the quarter ending Q4 2025, Prepaid Assets fell 44.3% year-over-year to $396000.0; the trailing twelve-month figure through Dec 2025 stood at $396000.0 (down 44.3% YoY), and the FY2025 full-year result was $429000.0, down 53.92% from the prior year.
- Prepaid Assets eased to $396000.0 in Q4 2025, from $429000.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $1.3 million in Q1 2024 to a low of $258198.0 in Q2 2021.
- A 5-year average of $628516.9 and a median of $558802.5 in 2022 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets surged 111.31% in 2023 and slumped 57.7% in 2025, its largest moves.
- Tracing AVXL's Prepaid Assets over 5 years: stood at $377860.0 in 2021, then surged by 73.51% to $655643.0 in 2022, then advanced by 15.31% to $756000.0 in 2023, then fell by 5.95% to $711000.0 in 2024, then sank by 44.3% to $396000.0 in 2025.
- Business Quant data shows AVXL's Prepaid Assets at $396000.0 in Q4 2025, $429000.0 in Q3 2025, and $448000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 396,000.00 |
| Sep 30, 2025 | 429,000.00 |
| Jun 30, 2025 | 448,000.00 |
| Mar 31, 2025 | 702,000.00 |
| Dec 31, 2024 | 711,000.00 |
| Sep 30, 2024 | 931,000.00 |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 756,000.00 |
| Sep 30, 2023 | 653,000.00 |
| Jun 30, 2023 | 827,572.00 |
| Mar 31, 2023 | 981,774.00 |
| Dec 31, 2022 | 655,643.00 |
| Sep 30, 2022 | 354,000.00 |
| Jun 30, 2022 | 461,963.00 |
| Mar 31, 2022 | 464,605.00 |
| Dec 31, 2021 | 377,860.00 |
| Sep 30, 2021 | 371,914.00 |
| Jun 30, 2021 | 258,198.00 |
| Mar 31, 2021 | 386,809.00 |